Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Biomedical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$738,294

126 payments

Through program year 2025, Center for Biomedical Research LLC is reported as receiving $738,294 in research payments, across 126 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $48,716 8
2024 Research $153,414 9
2023 Research $232,540 26
2022 Research $71,625 10
2021 Research $31,306 8
2020 Research $83,338 33
2019 Research $117,355 32

Breakdown

Who paid Research payments · program years 2019–2025
  1. Roche Diagnostics Operations, Inc. $243,287 16 payments
  2. United Therapeutics Corporation $226,734 73 payments
  3. ACADIA Pharmaceuticals Inc $109,456 12 payments
  4. Genentech, Inc. $39,703 8 payments
  5. AstraZeneca UK Limited $35,885 2 payments
  6. F. Hoffmann-La Roche AG $29,303 6 payments
  7. Genzyme Corporation $24,513 4 payments
  8. Pfizer Inc. $17,413 3 payments
  9. AbbVie, Inc. $12,000 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Rd006263 $243,287 16 payments
  2. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $66,226 12 payments
  3. Acp-103-047 $48,259 5 payments
  4. Acp-103-046 $42,644 5 payments
  5. A Multicenter Randomized Double-Blinded Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease $39,292 13 payments
  6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension PH in Heart Failure With Preserved Ejection Fraction Hfpef $36,232 7 payments
  7. CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease $35,885 2 payments
  8. 1L Nsclc DX All Comer Non Squamous $29,303 6 payments
  9. A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) $24,513 4 payments
  10. Alzheimer's Disease Master Pre Screener $24,203 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record